S-1/A: Tivic Health Registers 602,245 Shares for Resale by Key Investor, Highlighting Dilution Risks and Future Funding Strategy

Tivic Health Systems, Inc. filed an amended registration statement to allow a selling stockholder, Helena Global Investment Opportunities 1 Ltd., to resell up to 602,245 shares of common stock, stemming from a recent $8.4 million preferred stock and warrant purchase agreement.

Summary

• Tivic Health Systems, Inc. is a diversified therapeutics company with a bioelectronic program (ClearUP for sinus relief, developing non-invasive vagus nerve stimulation) and a TLR5 program (Entolimod for acute radiation syndrome and neutropenia).
• The filing is an amendment to a registration statement (Form S-1/A) for the resale of up to 602,245 shares of common stock by Helena Global Investment Opportunities 1 Ltd. (the Selling Stockholder).
• These shares include up to 540,958 shares convertible from Series B Non-Voting Convertible Preferred Stock and up to 61,287 shares from the exercise of Warrants, both issued in an initial tranche of a larger financing agreement.
• The company entered into a Purchase Agreement with the Selling Stockholder on April 29, 2025, for up to $8,400,000 through the sale of 8,400 shares of Series B Preferred Stock and associated Warrants across six tranches.
• The initial tranche closing occurred on June 25, 2025, where the Selling Stockholder paid $700,000 for 700 shares of Series B Preferred and Warrants to purchase 61,287 shares of common stock.
• The company will not receive proceeds from the Selling Stockholder's resale of shares, but will receive the exercise price if the Warrants are exercised.
• The Series B Preferred Stock carries a 10% cumulative annual dividend, ranks senior to common and Series A preferred, and is convertible into common stock at a conversion price not lower than $1.294 per share.
• Future tranches of the financing are contingent on the common stock price meeting or exceeding a $1.294 floor price for five consecutive trading days.
• The Selling Stockholder is limited to converting/exercising shares up to 19.99% of outstanding common stock until stockholder approval is obtained, which the company has committed to seek.
• Craft Capital Management LLC, as placement agent, received an 8% cash fee and warrants equal to 6% of funds received from the Selling Stockholder, including 10,000 warrants with an exercise price of $4.20 issued on June 25, 2025.
• The company has undergone two reverse stock splits: 1-for-17 on March 7, 2025, and 1-for-100 on August 23, 2023.
• As of July 23, 2025, 1,040,848 shares of common stock were outstanding, with an estimated 1,643,093 shares outstanding after full conversion/exercise of the initial tranche securities.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the 'going concern' warning from auditors, significant potential dilution from the registered shares, and the fact that the company receives no direct proceeds from this specific resale. While there are positive developments in product pipeline and strategic acquisitions, the financial stability concerns and dilution risks outweigh them in the context of an investment decision based on this filing.

Positives

• Secured an initial $700,000 in funding from Helena Global Investment Opportunities 1 Ltd. as part of a larger $8.4 million potential financing agreement.
• Acquired worldwide exclusive license rights to Entolimod for Acute Radiation Syndrome (ARS) and an exclusive option for five additional indications, including neutropenia, which has been exercised.
• Entolimod has received FDA Fast Track and Orphan Drug designation for ARS, indicating potential for expedited review and market exclusivity.
• The company's bioelectronic product, ClearUP, is FDA-approved for temporary relief of sinus pain and congestion, representing the first FDA-approved bioelectronic treatment for these indications.
• Encouraging initial clinical validation study results for non-invasive cervical Vagus Nerve Stimulation (ncVNS) showing increased heart rate variability and reduced anxiety-consistent brain activity.
• Strategic partnerships with institutions like Feinstein Institute for Bioelectronic Medicine and healthcare growth strategy firms like Fletcher Spaght to advance ncVNS technology and identify market opportunities.
• The company is actively preparing for a Biologics License Application (BLA) for Entolimod and a Phase 2 clinical study for neutropenia, indicating progress in its clinical pipeline.

Negatives

• The company will not receive any proceeds from the resale of shares by the Selling Stockholder under this prospectus, limiting direct capital infusion from this specific offering.
• The issuance of shares upon conversion of Series B Preferred and exercise of Warrants may cause substantial dilution to existing stockholders.
• The sale of a significant number of shares (up to 602,245) by the Selling Stockholder could depress the market price of the common stock.
• Future tranches of the $8.4 million financing are contingent on the common stock price remaining above a $1.294 floor, introducing uncertainty regarding full capital realization.
• The Selling Stockholder's ability to convert Series B Preferred and exercise Warrants is capped at 19.99% of outstanding common stock until stockholder approval is obtained, potentially delaying full conversion/exercise.
• The auditor's report contains an explanatory paragraph describing conditions that raise substantial doubt about the company's ability to continue as a going concern, indicating significant financial challenges.

Risks

• Conditions precedent in the Purchase Agreement may limit the company's ability to sell all securities under the agreement.
• Investors purchasing shares at different times from the Selling Stockholder may pay different prices and experience varying levels of dilution.
• The sale of a substantial number of common stock shares by the Selling Stockholder could lead to a decline in the company's stock price.
• Management has broad discretion over the use of net proceeds from warrant exercises (if any), which may not be invested successfully.
• Future equity offerings could result in additional dilution for existing stockholders.
• Uncertainty related to acquisitions, governmental regulation, and managing and maintaining growth.
• Volatility of the company's stock price.
• Uncertainty regarding the commercial viability of product candidates.
• Challenges in securing additional financing.
• Risk of not being able to continue as a going concern.
• Risk of not being able to sell all shares of Series B Preferred Stock or register and maintain registration of issuable shares.
• The Selling Stockholder's exercise of Warrants may never occur.
• Difficulty in maintaining compliance with Nasdaq Capital Market listing requirements.

Future Outlook

The company plans to prioritize targets for disease-specific trials for its non-invasive cervical Vagus Nerve Stimulation (ncVNS) technology in the second half of 2025. For its TLR5 program, the immediate focus is on validating the manufacturing process for Entolimod, including first lot manufacturing and bioequivalency testing, to support a Biologics License Application (BLA) submission to the FDA. The company also anticipates opportunities to market Entolimod for emergency use outside the United States prior to BLA approval and is preparing to file an Investigational New Drug (IND) application to initiate a Phase 2 clinical study for Entolimod for the treatment of neutropenia. The company has committed to filing a proxy statement to obtain stockholder approval for issuing additional shares related to the Helena financing.

Management Comments

• Our bioelectronic program is developing non-invasive medical devices to meaningfully improve treatment options in neurologic, cardiac and autonomic-related diseases.
• Our TLR5 program focuses on immunotherapeutics to activate underactive immune systems.
• We are preparing to file an investigational new drug (IND) application and to initiate a phase 2 clinical study for Entolimod for the treatment of neutropenia.
• We intend to overlay the results of the clinical research with our proprietary market research to prioritize targets for disease-specific trials planned for the second half of 2025.

Industry Context

Tivic Health operates in the growing fields of bioelectronic medicine and immunotherapeutics. Its ClearUP device positions it in the over-the-counter medical device market for sinus conditions. The company's focus on non-invasive vagus nerve stimulation (ncVNS) aligns with a rapidly expanding market, with forecasts suggesting the VNS market could reach $21 billion in five years, driven by both implanted and non-invasive technologies for conditions like depression, epilepsy, and rheumatoid arthritis. The acquisition of Entolimod places Tivic in the biodefense and oncology sectors, particularly with its Fast Track and Orphan Drug designations for Acute Radiation Syndrome, a niche but critical area, and its expansion into neutropenia treatment, a broader oncology support market.

Comparison to Industry Standards

• The Vagus Nerve Stimulation (VNS) market is forecasted to be worth $21 billion in the next five years, growing at a compounded annual growth rate of 10.6%, indicating a strong growth trajectory for Tivic's ncVNS program compared to the overall market.
• Implanted VNS stimulators from other companies have been approved for or are nearing approval for conditions such as depression, post-traumatic stress disorder, epilepsy, chronic stroke, and rheumatoid arthritis, setting a precedent for VNS technology adoption and reimbursement pathways that Tivic's non-invasive approach could leverage.
• Entolimod's Fast Track and Orphan Drug designations by the FDA for Acute Radiation Syndrome (ARS) are significant regulatory achievements, comparable to other companies developing treatments for rare or critical conditions, potentially accelerating its path to market and offering market exclusivity benefits.
• The prior investment of $140 million in Entolimod and Entolasta, including $35.6 million from U.S. government agencies (Department of Defense, NASA, NIH, Department of Army), suggests a level of validation and strategic importance for these assets, aligning with substantial R&D investments seen in late-stage drug development across the industry.

Management Changes

Corporate Governance

Related Party Transactions

• Securities Purchase Agreement with Helena Global Investment Opportunities 1 Ltd. (Selling Stockholder) for up to $8.4 million in Series B Preferred Stock and Warrants.
• Registration Rights Agreement with Helena Global Investment Opportunities 1 Ltd. to register shares for resale.
• Engagement Letter with Craft Capital Management LLC (placement agent) for services related to the Helena offering, including 8% cash fee and 6% warrants.
• Exclusive License Agreement and Securities Purchase Agreement with Statera Biopharma, Inc. for Entolimod license rights, involving cash payment of $300,000 and equity consideration (945,785 common shares and 359.6691 Series A Preferred shares).
• Securities Purchase Agreement with Statera and Avenue Venture Opportunities Fund, L.P. for the neutropenia indication milestone payment, involving equity (55,704 common shares and 131.1267 Series A Preferred shares).
• Equity Purchase Agreement with Mast Hill Fund, L.P. for potential sale of up to $25 million in common stock, including issuance of 29,800 restricted common shares as commitment shares.

Stakeholder Impact

• **Shareholders:** Face significant potential dilution from the conversion of Series B Preferred Stock and exercise of Warrants, and potential downward pressure on share price due to the large volume of shares registered for resale. Existing shareholders' voting power may be diluted upon full conversion of Series B Preferred, although Series B is non-voting except for specific adverse changes.
• **Investors (Helena Global Investment Opportunities 1 Ltd.):** Gains the ability to resell a substantial block of shares, providing liquidity for their investment. Benefits from anti-dilution provisions in warrants and a right of first refusal/participation in future financings.
• **Employees:** The company's continued operations and strategic developments in bioelectronics and immunotherapeutics could provide job stability and growth opportunities. Equity incentive plans are in place to attract and retain talent.
• **Customers:** Continued development of products like ClearUP and clinical pipeline assets like ncVNS and Entolimod could lead to new or improved treatment options for various health conditions.
• **Creditors:** The 'going concern' warning from auditors indicates increased risk for creditors. The capital raise from Helena, if fully realized, could improve the company's financial position, but the Series B Preferred ranks senior to common stock in liquidation.

Next Steps

• Prioritize targets for disease-specific trials for ncVNS in the second half of 2025.
• Validate the manufacturing process for Entolimod, including first lot manufacturing and bioequivalency testing, for Biologics License Application (BLA) submission to the FDA.
• Prepare and file an Investigational New Drug (IND) application and initiate a Phase 2 clinical study for Entolimod for the treatment of neutropenia.
• File a proxy statement on Schedule 14A with the SEC to obtain stockholder approval for issuing additional shares related to the Helena financing, no later than 20 days from April 29, 2025.
• Consummate subsequent tranches of the Helena Purchase Agreement, contingent on stock price and stockholder approval.

Key Dates

Recommendation

While Tivic Health has promising product development in bioelectronics and immunotherapeutics, including FDA-approved products and Fast Track designations, the filing highlights significant financial risks. The auditor's 'going concern' warning is a major red flag, indicating substantial uncertainty about the company's ability to continue operations. Furthermore, this specific filing is for the resale of shares by a selling stockholder, meaning the company receives no direct proceeds from these sales, and the large volume of shares could exert downward pressure on the stock price, leading to significant dilution for existing shareholders. The future tranches of the capital raise are contingent on stock price performance, adding further uncertainty. Given the high risk profile and the immediate dilution concerns, a 'hold' recommendation is appropriate for existing investors, while new investors should exercise extreme caution and conduct thorough due diligence beyond this filing.

Keywords

Tivic Health Systems, TIVC, SEC filing, S-1/A, resale prospectus, common stock, Series B Preferred Stock, warrants, dilution, capital raise, Helena Global Investment Opportunities, Craft Capital Management, bioelectronic devices, ClearUP, vagus nerve stimulation, ncVNS, immunotherapeutics, TLR5 agonist, Entolimod, acute radiation syndrome, neutropenia, FDA Fast Track, Orphan Drug designation, Nasdaq Capital Market, going concern, stock split